Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it?
作者信息
Trkulja Vladimir
机构信息
Department of Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia.
出版信息
Br J Clin Pharmacol. 2022 Jul;88(7):3539-3541. doi: 10.1111/bcp.15283. Epub 2022 Mar 2.
Abstract
摘要
相似文献
1
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it?托珠单抗降低重症 COVID-19 患者死亡率：我们应如何对其进行分级？
Br J Clin Pharmacol. 2022 Jul;88(7):3539-3541. doi: 10.1111/bcp.15283. Epub 2022 Mar 2.
2
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.托珠单抗治疗期间伴 MOG 抗体相关疾病的良性 SARS-CoV-2 感染。
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
3
[COVID-19: Still a place for tocilizumab?].[新型冠状病毒肺炎：托珠单抗仍有一席之地？]
Rev Med Interne. 2021 Feb;42(2):73-78. doi: 10.1016/j.revmed.2020.11.016. Epub 2020 Nov 27.
4
Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center.托珠单抗治疗重症和危重症 COVID-19 患者的死亡率的影响：三级医疗中心的经验。
Rev Invest Clin. 2022 Jan 3;74(1):40-50. doi: 10.24875/RIC.21000404.
5
Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab.接受托珠单抗治疗的2019冠状病毒病（COVID-19）患者的结局异质性
Clin Infect Dis. 2022 Apr 28;74(8):1504. doi: 10.1093/cid/ciab816.
6
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.托珠单抗治疗 COVID-19 患者的疗效和安全性：一项实时系统评价和荟萃分析，首次更新。
Clin Microbiol Infect. 2021 Aug;27(8):1076-1082. doi: 10.1016/j.cmi.2021.04.019. Epub 2021 Apr 27.
7
Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM.回复：在炎症标志物升高的住院COVID-19患者中早期使用托珠单抗；COVIDSTORM研究。
Clin Microbiol Infect. 2022 Nov;28(11):1519. doi: 10.1016/j.cmi.2022.06.013. Epub 2022 Jun 20.
8
Rational use of tocilizumab in COVID-19.
Ann Rheum Dis. 2022 Nov;81(11):e213. doi: 10.1136/annrheumdis-2020-218519. Epub 2020 Jul 31.
9
Tocilizumab prescribing criteria for COVID-19 patients.COVID-19患者的托珠单抗处方标准。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
10
Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia.测试托珠单抗对新冠肺炎肺炎患者的疗效。
J Comp Eff Res. 2021 Jun;10(8):625-627. doi: 10.2217/cer-2021-0050. Epub 2021 Apr 23.
本文引用的文献
1
Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials.托珠单抗对比 COVID-19 标准治疗/安慰剂治疗患者的疗效和安全性：一项随机临床试验的系统评价和荟萃分析。
Br J Clin Pharmacol. 2022 May;88(5):1955-1963. doi: 10.1111/bcp.15124. Epub 2021 Nov 30.
2
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.COVID-19 住院患者中使用白细胞介素 6 拮抗剂与死亡率的关系：一项荟萃分析。
JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330.
3
How to perform a meta-analysis with R: a practical tutorial.如何使用 R 进行荟萃分析：实用教程。
Evid Based Ment Health. 2019 Nov;22(4):153-160. doi: 10.1136/ebmental-2019-300117. Epub 2019 Sep 28.
4
A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses.模拟随机效应荟萃分析中异质性方差估计量的比较。
Res Synth Methods. 2019 Mar;10(1):83-98. doi: 10.1002/jrsm.1316. Epub 2018 Sep 6.
5
The Hartung-Knapp modification for random-effects meta-analysis: A useful refinement but are there any residual concerns?用于随机效应荟萃分析的哈通-克纳普修正法：一项有用的改进，但仍有任何遗留问题吗？
Stat Med. 2017 Nov 10;36(25):3923-3934. doi: 10.1002/sim.7411. Epub 2017 Jul 26.
6
Plea for routinely presenting prediction intervals in meta-analysis.呼吁在荟萃分析中常规呈现预测区间。
BMJ Open. 2016 Jul 12;6(7):e010247. doi: 10.1136/bmjopen-2015-010247.
7
Methods to estimate the between-study variance and its uncertainty in meta-analysis.在荟萃分析中估计研究间方差及其不确定性的方法。
Res Synth Methods. 2016 Mar;7(1):55-79. doi: 10.1002/jrsm.1164. Epub 2015 Sep 2.
8
Small studies are more heterogeneous than large ones: a meta-meta-analysis.小样本研究比大样本研究更具异质性：一项元分析研究。
J Clin Epidemiol. 2015 Aug;68(8):860-9. doi: 10.1016/j.jclinepi.2015.03.017. Epub 2015 Apr 2.
9
The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method.哈特ung-knapp-sidik-jonkman 方法进行随机效应荟萃分析是直接的，并且明显优于标准的德西蒙迪安-莱尔方法。
BMC Med Res Methodol. 2014 Feb 18;14:25. doi: 10.1186/1471-2288-14-25.
10
A re-evaluation of random-effects meta-analysis.随机效应荟萃分析的重新评估。
J R Stat Soc Ser A Stat Soc. 2009 Jan;172(1):137-159. doi: 10.1111/j.1467-985X.2008.00552.x.
Zotero 插件